EGFR and lung adenocarcinoma: Of the 11 patients with MRD-positive lung adenocarcinoma, 6 (6/11, 54.55%) were treated with chemotherapy (AP regimen), and 5 (5/11, 45.45%) were treated with EGFR-TKIs (1 with oral gefitinib and 5 cases of oral osimertinib).